Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
License and collaboration revenue	$ 35,000	$ 0	$ 35,000	$ 12,595
Total revenue	35,000	0	35,000	12,595
Operating expenses:
Research and development expenses	36,709	29,186	71,238	54,885
General and administrative expenses	12,457	13,435	25,160	25,385
Total operating expenses	49,166	42,621	96,398	80,270
Loss from operations	(14,166)	(42,621)	(61,398)	(67,675)
Other income and expenses:
Grant income	522	799	1,472	1,534
Research and development tax credits	893	386	1,696	729
Interest income	7,817	8,042	15,203	15,893
Other income , net	67	326	2,158	2,099
Loss before income tax expense	(4,867)	(33,068)	(40,869)	(47,420)
Income tax expense	(2,261)	(1,232)	(4,475)	(2,431)
Net loss	$ (7,128)	$ (34,300)	$ (45,344)	$ (49,851)
Basic net loss per share	$ (0.18)	$ (0.96)	$ (1.2)	$ (1.39)
Diluted net loss per share	$ (0.18)	$ (0.96)	$ (1.2)	$ (1.39)
Weighted-average common shares outstanding - basic	39,699,053	35,768,952	37,771,084	35,742,641
Weighted-average common shares outstanding - diluted	39,699,053	35,768,952	37,771,084	35,742,641
Net Income (Loss)	$ (7,128)	$ (34,300)	$ (45,344)	$ (49,851)
Foreign currency translation adjustments	(151)	104	(2,416)	(1,902)
Unrealized loss on available-for-sale securities	(72)	(1,722)	(906)	(1,620)
Comprehensive loss	$ (7,351)	$ (35,918)	$ (48,666)	$ (53,373)